Axcella Therapeutics Puts Development Of NASH Program Aside, Reduces Workforce By 85%


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


  • Axcella Health Inc (NASDAQ:AXLA) announced organizational and program updates, including a reprioritization of its programs for Long COVID Fatigue and Nonalcoholic Steatohepatitis (NASH) and a restructuring of operations.
  • Axcella's Phase 2a trial results demonstrate the potential of AXA1125 for Long COVID fatigue. 
  • Subjects who received AXA1125 had improvements in mental and physical fatigue measures that were statistically significant and clinically relevant compared to those who received a placebo
  • The company is engaged in ongoing and productive reviews with regulators in the U.S. and Europe, and the company is aiming to advance its Long COVID Fatigue program into a potential registration trial.
  • Axcella will discontinue its ongoing Phase 2b trial of AXA1125 in NASH while keeping the option to revisit this program should resource availability change. 
  • Related: Axcella Shares Jump Despite Mixed Bag Data From Mid-Stage NASH Trial.
  • Axcella is reducing its workforce by 85%. Among the departing employees are Bob Crane, Chief Financial Officer, and Virginia Dean, Chief People Officer.
  • Axcella reached an agreement with SLR Investment Corp. (f/k/a Solar Capital Ltd) to pay down the debt obligations of the previous agreement.
  • The company has initiated a process to explore a range of strategic alternatives. It works with an investment bank as a strategic advisor for this process. 
  • Price Action: AXLA shares closed at $0.89 on Wednesday.

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefs